TLDR Palantir reported Q4 revenue of $1.41 billion, beating Wall Street’s estimate of $1.33 billion, with 70% year-over-year growth Adjusted earnings per share TLDR Palantir reported Q4 revenue of $1.41 billion, beating Wall Street’s estimate of $1.33 billion, with 70% year-over-year growth Adjusted earnings per share

Palantir (PLTR) Stock: Q4 Earnings Crush Estimates on AI and Government Demand

3 min read

TLDR

  • Palantir reported Q4 revenue of $1.41 billion, beating Wall Street’s estimate of $1.33 billion, with 70% year-over-year growth
  • Adjusted earnings per share came in at $0.25, exceeding the expected $0.23, while full-year revenue reached $4.48 billion
  • U.S. commercial revenue jumped 137% to $507 million and U.S. government revenue grew 66% to $570 million
  • The company issued Q1 revenue guidance of $1.532-$1.536 billion versus the $1.32 billion consensus, and fiscal 2026 guidance of $7.182-$7.198 billion versus $6.22 billion expected
  • Shares rose 5% after hours Monday and jumped an additional 12% in premarket trading Tuesday

Palantir delivered a knockout punch to Wall Street expectations when it reported fourth-quarter results on Monday. The AI and data analytics company posted numbers that left analysts scrambling to revise their models upward.

Revenue hit $1.41 billion for the quarter. That crushed the $1.33 billion consensus estimate.

The company reported adjusted earnings of $0.25 per share. Analysts had penciled in $0.23.


PLTR Stock Card
Palantir Technologies Inc., PLTR

Year-over-year revenue growth clocked in at 70%. That’s the kind of expansion that makes investors sit up and take notice.

Full-year revenue reached $4.48 billion. The Denver-based firm continues to ride the wave of AI adoption across enterprise and government sectors.

The stock reacted accordingly. Shares jumped 5% in after-hours trading Monday. Tuesday’s premarket session saw an additional 12% surge.

Domestic Sales Power the Beat

The real story lives in the geographic breakdown. U.S. commercial revenue exploded 137% to $507 million. Analysts had expected $479 million.

U.S. government revenue wasn’t far behind. That segment grew 66% to $570 million, beating the $522 million estimate.

Karp highlighted the government segment’s momentum. He pointed to ongoing adoption by the Department of Defense, Internal Revenue Service, and Department of Homeland Security.

Guidance Blows Past Expectations

The forward outlook might be even more impressive than the quarterly results. First-quarter revenue guidance came in at $1.532 billion to $1.536 billion. The Street had been modeling $1.32 billion.

Full-year fiscal 2026 guidance landed between $7.182 billion and $7.198 billion. Analysts were expecting $6.22 billion. That’s a massive upward revision.

William Blair analyst Louis DiPalma upgraded the stock to Outperform from Market Perform on Monday. He cited the recent sell-off as making the valuation “more reasonable.”

The shares had fallen roughly 12% over the past month. That drop came as software stocks broadly declined on concerns about AI disruption to established players.

He described Palantir as “a different species of company” with products and culture built for the current AI boom. The company’s early investments in AI technology are now paying dividends as businesses and government agencies rush to implement these tools.

Demand has become so strong that Karp noted the company has had to be selective about its engagements. “If you’re not spending it on this, you’re not spending on something that is part of keeping up with momentum,” he said.

The company scheduled an earnings call with analysts for 5 p.m. ET Monday to discuss the results in detail.

The post Palantir (PLTR) Stock: Q4 Earnings Crush Estimates on AI and Government Demand appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge

Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge

The surge follows a difficult August, when investors pulled out more than $750 million while rotating capital into Ethereum-focused funds. […] The post Bitcoin ETFs Outpace Ethereum With $2.9B Weekly Surge appeared first on Coindoo.
Share
Coindoo2025/09/18 01:15
CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
The FDA Is Trying To Make Corporate Free Speech Situational

The FDA Is Trying To Make Corporate Free Speech Situational

The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…
Share
BitcoinEthereumNews2025/09/18 06:29